ASCO 2015 Highlights

“Unheard of” Results with Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer
By Phoebe Starr
Breast Cancer
April 2020, Vol 11, No 2
San Antonio, TX—The novel antibody– drug conjugate trastuzumab deruxtecan (Enhertu) achieved “unprecedented” objective response rates of 60.9%, a median duration of response of 14.8 months, and a median progression- free survival (PFS) of 16.4 months in heavily pretreated patients with HER2-positive metastatic breast cancer, according to the results of the phase 2 DESTINY-Breast01 trial. The disease control rate was 97% in these patients whose disease progressed while receiving HER2-targeted agents, such as trastuzumab (Herceptin), ado-trastuzumab emtansine (T-DM1; Kadcyla), or pertuzumab (Perjeta).
Read Article
Gemcitabine-Cisplatin Combination a New Standard in Pancreatic Cancer with Germline BRCA or PALB2 Mutation
By Wayne Kuznar
ASCO, Gastrointestinal Cancers, Pancreatic Cancer
April 2020, Vol 11, No 2

San Francisco, CA—Platinum-based therapy represents a new standard of care in patients with pancreatic cancer and germline BRCA or PALB2 mutation, based on data reported at the 2020 Gastrointestinal Cancers Symposium. The findings were published simultaneously in the Journal of Clinical Oncology (O’Reilly EM, et al. J Clin Oncol. 2020 Jan 24. Epub ahead of print).

Read Article
Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation
By Wayne Kuznar
ASCO, Colorectal Cancer, Gastrointestinal Cancers
April 2020, Vol 11, No 2

San Francisco, CA—The combination of encorafenib (Braftovi) plus cetuximab (Erbitux), with or without binimetinib (Mektovi), improved the quality of life based on patient-reported assessments better than current standard of care in the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation, according to the BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Read Article
April 22, 2020: Wholesale Supply Channels: COVID-19 Impact on Cancer Care and Road to Recovery
April 22, 2020: Wholesale Supply Channels: COVID-19 Impact on Cancer Care and Road to Recovery
By Brian Ansay; Mick Besse, MBA; Kevan Corbett; Patrick Schmidt; Burt Zweigenhaft, PhD, D.Litt
COVID-19
How does COVID-19 affect the distribution channels that deliver crucial medicine and other supplies for patients with cancer? In ths discussion, thought leaders in the wholesale drug distribution segment focused on the disruption and interventions brought about by the COVID-19 pandemic.
Read Article
April 17, 2020: Revenue Cycle Management: COVID-19 Impact on Cancer Care and Road to Recovery
April 17, 2020: Revenue Cycle Management: COVID-19 Impact on Cancer Care and Road to Recovery
By Brian Gockerman, MBA; Parag Shah; Burt Zweigenhaft, PhD, D.Litt
COVID-19
In this webcast, Brian Gockerman, Managing Director at Unlimited Systems, begins by discussing the stabilization of cancer care programs, the potential implications of telehealth, the decline of newly referred patients, and what to prepare for in the future. Parag Shah, President, Practice Solutions at Integra Connect, continues the conversation by discussing how to keep your team engaged when working remotely, the shift of solution providers and telehealth, payer challenges, and solutions to some of these issues.
Read Article
The Association for Value-Based Cancer Care Launches Webinar Series: COVID-19 Impact on the Cancer Care Delivery Ecosystem
COVID-19
Cranbury, NJ – Fueled by the success of its live webcast earlier this month, the Association for Value-Based Cancer Care (AVBCC) is launching a free webinar series titled COVID-19 Impact on the Cancer Care Delivery Ecosystem.
Read Article
Welcoming Opening Remarks
By Clifford Hudis, MD, FACP, FASCO; Burt Zweigenhaft, PhD, D.Litt
COVID-19
The Association for Value-Based Cancer Care (AVBCC) webcast was introduced by Dr Zweigenhaft, Founder of AVBCC, who assembled an exceptional group of experts from across the country to discuss the COVID-19 outbreak and its impact on the healthcare industry. After a few quick welcoming remarks to allow more time for the fast-moving presentations, Dr Zweigenhaft introduced Dr Hudis, who briefly presented ASCO’s outlook on the crisis.
Read Article
Washington and Public Policy: The COVID-19 Pandemic
By Scott Gottlieb, MD; Jayson Slotnik, JD, MPH
COVID-19
Mr Slotnik opened the session with an inside look at Washington, addressing some of the changes to oncology care policies and operations from the COVID-19 pandemic. He outlined a quick overview of the initiatives from the Centers for Medicare & Medicaid Services (CMS), including new guidelines and the easing of some restrictions on physicians’ options for telemedicine.
Read Article
Community Care Providers and COVID-19
By Lucio Gordan, MD; Ted Okon, MBA; Jeff Patton, MD
COVID-19
Up to 65% of cancer care is delivered via community cancer centers that are not part of a hospital or academic center. These centers are feeling the impact of COVID-19 as the pandemic reshapes the way these facilities provide care to patients.
Read Article
Comprehensive Cancer Care Systems
By Pat Basu, MD, MBA; Robert W. Carlson, MD; Christian Downs, MHA, JD
COVID-19
According to the NCCN, an alliance of 30 leading academic cancer centers in the United States, the data suggest that although patients with cancer are not more susceptible to infection from the new coronavirus than other people, they do have much worse outcomes. “Prevention is thus the key for oncology patients,” Dr Carlson said.
Read Article

Page 77 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.